Terns Pharmaceuticals (TERN) News Today $6.80 -0.18 (-2.58%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?December 16 at 2:05 PM | insidermonkey.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Stake Reduced by Fmr LLCFmr LLC decreased its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 57.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,172,524 shares of the company's stock after selling 1,594,572 shares duringDecember 12, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up After Insider Buying ActivityDecember 12, 2024 | americanbankingnews.comTerns Pharmaceuticals CEO & Director Acquires 423% More StockDecember 11, 2024 | uk.finance.yahoo.comAmy L. Burroughs Purchases 15,450 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockDecember 10, 2024 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Terns Pharmaceuticals (TERN)December 6, 2024 | markets.businessinsider.comWalleye Capital LLC Takes $1.55 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Walleye Capital LLC acquired a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 185,795 shares of the company's stock, valued at approDecember 5, 2024 | marketbeat.comTerns's stock soars as analysts cheer leukemia data — and predict more gainsDecember 4, 2024 | marketwatch.comParkman Healthcare Partners LLC Grows Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Parkman Healthcare Partners LLC increased its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 39.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 545,751 shares of the company's stock after buying an additionDecember 4, 2024 | marketbeat.com168,564 Shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Acquired by Cinctive Capital Management LPCinctive Capital Management LP bought a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 168,564 shares of the company's stock, valued at approximately $1,406,000. CDecember 4, 2024 | marketbeat.comTerns Pharmaceuticals price target raised to $20 from $17 at OppenheimerDecember 3, 2024 | markets.businessinsider.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)December 2, 2024 | globenewswire.comQuantbot Technologies LP Purchases 117,079 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Quantbot Technologies LP raised its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 3,114.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 120,838 shares of the company's stoDecember 2, 2024 | marketbeat.comBellevue Group AG Acquires New Shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Bellevue Group AG acquired a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,042,135 shares of the company's stock, valDecember 1, 2024 | marketbeat.comAcuta Capital Partners LLC Has $4.06 Million Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Acuta Capital Partners LLC boosted its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 31.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 487,000 shares of the company's stock after acquiring aNovember 28, 2024 | marketbeat.comWeight-loss-drug makers’ stocks get a boost from new Biden coverage proposal, but will it hold up?November 26, 2024 | msn.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued aNovember 25, 2024 | marketbeat.comTerns Pharmaceuticals on the Brink of Innovation with Upcoming TERN-701 Data ReleaseNovember 22, 2024 | markets.businessinsider.comTelemark Asset Management LLC Purchases Shares of 300,000 Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Telemark Asset Management LLC acquired a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 300,000 shares of the company's stock, valued at approximatelNovember 22, 2024 | marketbeat.com104,535 Shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Bought by Quest Partners LLCQuest Partners LLC purchased a new stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 104,535 shares of the company's stock, valued at apNovember 21, 2024 | marketbeat.comTerns Pharmaceuticals Appoints Heather Turner to BoardNovember 19, 2024 | markets.businessinsider.comTerns Pharmaceuticals Appoints Heather Turner, J.D., to Board of DirectorsNovember 18, 2024 | globenewswire.comTerns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 8.7% - Should You Sell?Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 8.7% - Should You Sell?November 15, 2024 | marketbeat.comWe Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business GrowthNovember 15, 2024 | finance.yahoo.comWhat is HC Wainwright's Forecast for TERN FY2024 Earnings?Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Stock analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Terns Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per shaNovember 15, 2024 | marketbeat.comBrokers Issue Forecasts for TERN Q1 EarningsTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Terns Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst E. Arce anticipates that the company will earn ($November 14, 2024 | marketbeat.comTerns Pharmaceuticals: Promising Clinical Developments and Strong Financial Position Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comPromising Phase 1/2 Study and Strong Financials Drive Buy Rating for Terns PharmaceuticalsNovember 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Revolution Medicines (RVMD)November 8, 2024 | markets.businessinsider.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by AnalystsTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have issuedOctober 31, 2024 | marketbeat.comOppenheimer Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)Oppenheimer started coverage on shares of Terns Pharmaceuticals in a report on Thursday. They issued an "outperform" rating and a $82.00 target price on the stock.October 31, 2024 | marketbeat.comTerns Pharmaceuticals: Another Potential GLP-1 EntrantOctober 21, 2024 | seekingalpha.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Short Interest UpdateTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,910,000 shares, an increase of 30.6% from the September 15th total of 3,760,000 shares. Approximately 8.3% of the shares of the company are sold short. Based on an average trading volume of 1,930,000 shares, the days-to-cover ratio is presently 2.5 days.October 14, 2024 | marketbeat.comMarshall Wace LLP Decreases Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Marshall Wace LLP cut its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 86.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,985 shares of the company's stock after sellinOctober 13, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 6.2% - Should You Sell?Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 6.2% - What's Next?October 10, 2024 | marketbeat.comRenaissance Technologies LLC Takes Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Renaissance Technologies LLC bought a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 87,500 shares of the company's stoOctober 10, 2024 | marketbeat.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)October 7, 2024 | globenewswire.comTerns Pharma (NASDAQ:TERN) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Acquired by Point72 Asset Management L.P.Point72 Asset Management L.P. boosted its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 21.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,690,376 shares of the company's stock after puSeptember 30, 2024 | marketbeat.comShort Interest in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Increases By 41.4%Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 3,760,000 shares, an increase of 41.4% from the August 31st total of 2,660,000 shares. Based on an average trading volume of 1,950,000 shares, the short-interest ratio is currently 1.9 days. Currently, 6.4% of the shares of the company are sold short.September 27, 2024 | marketbeat.comGreat Point Partners LLC Sells 160,569 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Great Point Partners LLC lessened its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 12.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,149,406 shares of the company's stock aftSeptember 24, 2024 | marketbeat.comTerns Pharmaceuticals Inc (430.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Purchased by Bank of New York Mellon CorpBank of New York Mellon Corp increased its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 56.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 176,673 shares of the companSeptember 21, 2024 | marketbeat.comThis Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss TreatmentsSeptember 18, 2024 | fool.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Buys $4,999,995.00 in StockSeptember 18, 2024 | insidertrades.comTerns Pharmaceuticals (NASDAQ:TERN) Trading Up 6.1%Terns Pharmaceuticals (NASDAQ:TERN) Trading 6.1% HigherSeptember 17, 2024 | marketbeat.comOrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals IncSeptember 17, 2024 | finance.yahoo.comWith 55% ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) boasts of strong institutional backingSeptember 17, 2024 | finance.yahoo.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up to $8.95Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up to $8.95September 16, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Earns "Outperform" Rating from BMO Capital MarketsBMO Capital Markets reaffirmed an "outperform" rating and set a $26.00 price objective (up from $19.00) on shares of Terns Pharmaceuticals in a research note on Monday.September 16, 2024 | marketbeat.com Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. TERN Media Mentions By Week TERN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TERN News Sentiment▼0.460.71▲Average Medical News Sentiment TERN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TERN Articles This Week▼53▲TERN Articles Average Week Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Longboard Pharmaceuticals News Today NewAmsterdam Pharma News Today IDEAYA Biosciences News Today Recursion Pharmaceuticals News Today Centessa Pharmaceuticals News Today Apogee Therapeutics News Today ImmunityBio News Today Wave Life Sciences News Today Mirum Pharmaceuticals News Today Akero Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TERN) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
